Plain-English translation of NCT06802718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether polyethylene glycol -alpha, given as weekly injections for 6 months, can help prevent acute myeloid leukemia from returning after you've completed chemotherapy. You'll be randomly assigned to either receive this medication or to be monitored closely without it. The study wants to see if the medication can eliminate remaining leukemia cells that might otherwise cause a relapse.
Even after successful chemotherapy, some patients with favorable-risk acute myeloid leukemia still have a small number of leukemia cells that survive. This trial explores whether this medication can help destroy those remaining cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you're randomly assigned to the treatment group, you'll receive a weekly subcutaneous injection of the medication for 6 months. If you're in the control group, you'll have regular follow-up appointments to monitor your health without receiving this specific maintenance treatment. Either way, researchers will monitor you closely over 2 years to check for leukemia relapse, measure your blood counts, test for remaining leukemia cells, and track your overall health and survival.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China